FDA Approves New Pancreatic Cancer Treatment

The US Food and Drug Administration (FDA) has approved, with reservations, the new pancreatic cancer drug Onivyde manufactured by US drugmaker Merrimack for use in combination with leucovorin and fluorouracil.

The drug combination is being touted as a chemotherapeutic option for patients with advanced pancreatic cancer who are no longer responsive to gemcitabine-based treatments.

Merrimack CEO Robert Mulroy called the FDA approval “a pivotal milestone in our company's history, representing years of hard work and commitment to our mission of engineering new treatment options for cancer patients in need.”

Effectiveness of the treatment was evaluated in a randomized, three-arm study on more than 400 patients with metastatic pancreatic cancer. Results showed that patients treated with a combination of Onivyde and fluorouracil/leucovorin had delayed tumor growth compared with other participants in the trial who were treated with only fluorouracil/leucovorin or Onivyde alone.

Scientists said the results were encouraging because pancreatic cancer, due to the difficulty of diagnosing it early, is one of the deadliest cancers, and treatment options up to now have been limited.

The caveat is that, like most chemotherapeutic drugs, Onivyde comes with many side effects. Based on patient evaluation, the most common are said to include diarrhea, nausea and vomiting, fatigue, anorexia, stomatitis, immunosupression and fever. There is also a risk for decreased kidney function, sepsis and death, which is why the FDA has required labels with boxed warnings to alert prescribers to the risks for diarrhea and severe neutropenia.

Onivyde is also not meant to be used as a singular chemotherapeutic agent.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.